Neuropathy Clinical Trials

278 recruitingLast updated: June 9, 2026

There are 278 actively recruiting neuropathy clinical trials across 63 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Neuropathy Trials at a Glance

278 actively recruiting trials for neuropathy are listed on ClinicalTrialsFinder across 6 cities in 63 countries. The largest study group is Not Applicable with 112 trials, with the heaviest enrollment activity in Houston, Boston, and New York. Lead sponsors running neuropathy studies include M.D. Anderson Cancer Center, Riphah International University, and argenx.

Browse neuropathy trials by phase

Treatments under study

About Neuropathy Clinical Trials

Looking for clinical trials for Neuropathy? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 278 trials

Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled4 locationsNCT07304154
Recruiting
Not Applicable

WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention

Peripheral NeuropathyDiabetesDiabetic Foot Ulcer+1 more
Johns Hopkins University400 enrolled1 locationNCT05950659
Recruiting
Phase 2Phase 3

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC201 enrolled115 locationsNCT05327114
Recruiting
Phase 3

Trial of a Virtual Exercise-based Rehabilitation Program to Treat Persistent Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Chemotherapy-induced Peripheral Neuropathy (CIPN)
University Health Network, Toronto240 enrolled1 locationNCT07481149
Recruiting
Not Applicable

Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy Induced Peripheral NeuropathyCIPN - Chemotherapy-Induced Peripheral Neuropathy
Case Comprehensive Cancer Center90 enrolled1 locationNCT07219472
Recruiting
Not Applicable

Functional and Neuroprotective Effects of Restoring Lower Limb Sensation After Diabetic Peripheral Neuropathy

Diabetic Peripheral NeuropathyLower Extremity Amputee
VA Office of Research and Development15 enrolled1 locationNCT04658693
Recruiting
Not Applicable

Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2

Chemotherapy Induced Peripheral NeuropathyGynecologic Cancer
Duke University190 enrolled4 locationsNCT06139458
Recruiting

Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected

Optic NeuritisOptic NeuropathyVisual Loss
First Affiliated Hospital of Guangxi Medical University500 enrolled9 locationsNCT07623252
Recruiting
Not Applicable

Shortwave Intervention for Diabetic Peripheral Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial(SIDPN)

Diabetic Peripheral Neuropathy
Chongqing Medical University202 enrolled1 locationNCT07625007
Recruiting
Not Applicable

Ultrasound-Guided Nerve Hydrodissection for Diabetic Lower Limb Entrapment Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial

Diabetic Peripheral NeuropathyEntrapment Neuropathy
Chongqing Medical University266 enrolled1 locationNCT07625020
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Chronic Inflammatory Demyelinating Polyneuropathy
Dianthus Therapeutics256 enrolled168 locationsNCT06858579
Recruiting
Phase 3

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi160 enrolled123 locationsNCT06290141
Recruiting
Phase 4

Two Dose Levels of Privigen in Pediatric CIDP

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CSL Behring30 enrolled9 locationsNCT03684018
Recruiting

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

PolyneuropathyHereditary Transthyretin-mediated (hATTR) Amyloidosis
Alnylam Pharmaceuticals10 enrolled7 locationsNCT05040373
Recruiting
Phase 2

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

Breast CancerPeripheral Neuropathy
Montefiore Medical Center116 enrolled1 locationNCT07109817
Recruiting
Phase 1Phase 2

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

MELAS SyndromeLebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
George Washington University24 enrolled1 locationNCT06792500
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyCIDP
argenx160 enrolled56 locationsNCT07091630
Recruiting
Phase 2

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Chemotherapy Induced Neuropathic PainChemotherapy Induced Pain NeuropathyChemotherapy Induced Pain
Dogwood Therapeutics Inc.240 enrolled25 locationsNCT06848348
Recruiting

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

Urothelial CarcinomaMetastatic Urothelial CarcinomaNeuropathy
Memorial Sloan Kettering Cancer Center50 enrolled7 locationsNCT07390617
Recruiting
Not Applicable

Balance Rehabilitation With Modified Visual Input in Patients With Neuropathy

NeuropathyAtaxiaBalance; Distorted+1 more
Assistance Publique - Hôpitaux de Paris40 enrolled1 locationNCT03881930